Coya Therapeutics, Inc. Common Stock (COYA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $73.42M
Last updated: Nov 17, 2026 at 11:04 AM ET
Coya Therapeutics, Inc. Common Stock (COYA) Stock Forecast
Analysts expect Coya Therapeutics, Inc. Common Stock (COYA) to earn -$1.53 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.16M. Of 7 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 7 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 313.8%.
- Fiscal year ending Dec 31, 2026
- -$1.53
- EPS consensus, revenue $1.16M
- Fiscal year ending Dec 31, 2027
- -$1.92
- EPS consensus, revenue $4.80M
- Next report
- Mar 15, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.53 | -$1.53 to -$1.53 | 2 | $1.16M | $495000 to $3.74M | 6 |
| Dec 31, 2027 | -$1.92 | -$2.20 to -$1.64 | 3 | $4.80M | N/A | 5 |
Quarterly Estimates
The EPS consensus falls from -$0.40 for the quarter ending Dec 31, 2026 to -$0.48 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.40 | -$0.49 to -$0.33 | 9 | $512917 | N/A | 9 |
| Mar 31, 2027 | -$0.48 | -$0.52 to -$0.44 | 3 | $100000 | N/A | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.42.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.53 | -$1.37 | -$1.37 | -$1.37 | -$1.42 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.92 | -$1.92 | -$1.88 | -$1.88 | -$1.73 | N/A |
| Quarter ending Mar 31, 2027 | -$0.48 | -$0.48 | -$0.46 | -$0.46 | -$0.45 | N/A |
Frequently Asked Questions About COYA
What is the COYA stock forecast?
Consensus analyst estimates put Coya Therapeutics, Inc. Common Stock's EPS at -$1.53 for the fiscal year ending Dec 31, 2026, on revenue of $1.16M. The consensus rating from 7 analysts is Buy.
How do analysts rate COYA stock?
Of 7 analysts covering Coya Therapeutics, Inc. Common Stock, 0 rate it Strong Buy, 7 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from COYA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.53, with estimates from -$1.53 to -$1.53 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.92, with estimates from -$2.20 to -$1.64 from 3 analysts.
What revenue do analysts expect from Coya Therapeutics, Inc. Common Stock next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.16M, with estimates from $495000 to $3.74M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $4.80M.
How many analysts cover COYA?
7 analysts rate Coya Therapeutics, Inc. Common Stock stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
COYA pages: Overview, Earnings, Forecast, Financials, Competitors